INOTEK PHARMACEUTICALS CORP's ticker is and the CUSIP is 45780VAB8. A total of 9 filers reported holding INOTEK PHARMACEUTICALS CORP in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $7,148,000 | -40.0% | 7,000,000 | -44.4% | 0.22% | -37.5% |
| Q4 2018 | $11,906,000 | -21.3% | 12,600,000 | -7.4% | 0.35% | -1.9% |
| Q3 2018 | $15,130,000 | +19.2% | 13,600,000 | +7.9% | 0.36% | +40.8% |
| Q2 2018 | $12,692,000 | +86.3% | 12,600,000 | +80.0% | 0.26% | +131.8% |
| Q1 2018 | $6,812,000 | – | 7,000,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TFG Asset Management GP Ltd | 7,700,000 | $8,592,000 | 1.03% |
| Bruce & Co., Inc. | 2,000,000 | $2,220,000 | 0.43% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 13,600,000 | $15,130,000 | 0.36% |
| Orbimed Advisors | 7,000,000 | $7,788,000 | 0.09% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1,000,000 | $1,108,000 | 0.08% |
| Verition Fund Management LLC | 1,633,000 | $1,826,000 | 0.06% |
| Citadel Advisors | 11,250,000 | $12,462,000 | 0.01% |
| CREDIT SUISSE AG/ | 4,750,000 | $5,239,000 | 0.01% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |